Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells

Sirpa Leppä(University of Helsinki)

International Journal of Oncology

September 15, 2009

10.3892/ijo_00000434

Cited by 62

Related Papers

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

|The Lancet|2024|135

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

|The Lancet Haematology|2024|134

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

|Blood|2023|38

137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIAL

|Hematological Oncology|2025|1

Supplementary Table from Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment

|Unknown|2023|0